Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

被引：0
|
作者：
Michael A Postow
Diana M Cardona
Janis M Taube
Robert A Anders
Clive R Taylor
Jedd D Wolchok
Margaret K Callahan
Michael A Curran
Alexander M Lesokhin
Joseph F Grosso
Christine E Horak
John Cogswell
Jason S Simon
Ashok K Gupta
Mario Sznol
机构：
[1] Memorial Sloan-Kettering Cancer Center,Keck School of Medicine
[2] Duke University School of Medicine,undefined
[3] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,undefined
[4] University of Southern California,undefined
[5] Bristol-Myers Squibb,undefined
[6] Yale University School of Medicine and Yale Cancer Center,undefined
来源：
Journal of Translational Medicine | / 12卷 / Suppl 1期
关键词：
Ipilimumab; Tumor Infiltrate Lymphocyte; Advanced Melanoma; Myeloid Derive Suppressor Cell; Absolute Lymphocyte Count;
D O I：
10.1186/1479-5876-12-S1-O8
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.
    Callahan, Margaret K.
    Horak, Christine E.
    Curran, Michael A.
    Hollman, Travis
    Schaer, David A.
    Yuan, Jianda
    Lesokhin, Alexander M.
    Kitano, Shigehisa
    Hong, Quan
    Ariyan, Charlotte Eielson
    Busam, Klaus J.
    Feely, William
    Jure-Kunkel, Maria
    Grosso, Joseph
    Simon, Jason S.
    Korman, Alan J.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Sznol, Mario
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
    Wolchok, Jedd D.
    Kluger, Harriet M.
    Callahan, Margaret K.
    Postow, Michael Andrew
    Gordon, Ruth Ann
    Segal, Neil Howard
    Rizvi, Naiyer A.
    Lesokhin, Alexander M.
    Reed, Kathleen
    Burke, Matthew M.
    Caldwell, Anne
    Kronenberg, Stephanie Anne
    Agunwamba, Blessing
    Feely, William
    Hong, Quan
    Horak, Christine E.
    Korman, Alan J.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Sznol, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Phase 2 study of nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in patients with advanced melanoma
    Yamazaki, N.
    Tahara, H.
    Uhara, H.
    Moroi, Y.
    Kiyohara, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S868 - S868
  • [4] Combined nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab in the treatment of advanced melanoma (MEL) patients (pts): Safety and clinical activity
    Sznol, M.
    Callahan, M. K.
    Kluger, H.
    Postow, M. A.
    Burke, M.
    Hong, Q.
    Selby, M.
    Korman, A.
    Gupta, A.
    Wolchok, J. D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S866 - S866
  • [5] Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in Japanese patients with advanced melanoma: Preliminary report
    Yamazaki, N.
    Kiyohara, Y.
    Uhara, H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S110 - S110
  • [6] Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer
    Rajan, Arun
    Gulley, James L.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 403 - 405
  • [7] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC)
    Amin, A.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M. S.
    Rini, B.
    Mcdermott, D. F.
    Knox, J.
    Pal, S. K.
    Voss, M. H.
    Sharma, P.
    Kollmannsberger, C.
    Heng, D. Y. C.
    Spratlin, J.
    Shen, Y.
    Kurland, J. F.
    Gagnier, P.
    Hammers, H.
    BJU INTERNATIONAL, 2014, 114 : 2 - 2
  • [8] Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
    Grosso, Joseph
    Horak, Christine E.
    Inzunza, David
    Cardona, Diana M.
    Simon, Jason S.
    Gupta, Ashok Kumar
    Sankar, Vindira
    Park, Jong-Soon
    Kollia, Georgia
    Taube, Janis M.
    Anders, Robert
    Jure-Kunkel, Maria
    Novotny, Jim, Jr.
    Taylor, Clive R.
    Zhang, Xiaoling
    Phillips, Therese
    Simmons, Pauline
    Cogswell, John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Amin, Asim
    Plimack, Elizabeth R.
    Infante, Jeffrey R.
    Ernstoff, Marc S.
    Rini, Brian I.
    McDermott, David F.
    Knox, Jennifer J.
    Pal, Sumanta Kumar
    Voss, Martin Henner
    Sharma, Padmanee
    Kollmannsberger, Christian K.
    Heng, Daniel Yick Chin
    Spratlin, Jennifer L.
    Shen, Yun
    Kurland, John F.
    Gagnier, Paul
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL)
    Sosman, Jeffrey Alan
    Martin-Algarra, Salvador
    Wolchok, Jedd D.
    Sharfman, William Howard
    Bhatia, Shailender
    Hodi, F. Stephen
    Hwu, Wen-Jen
    Gajewski, Thomas
    Slingluff, Craig L.
    Kaufman, Howard
    Gupta, Manish
    McGirr, Analia
    Horak, Christine E.
    Ahlers, Christoph Matthias
    Wigginton, Jon M.
    Urba, Walter John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345